JAK Inhibition in COVID-19
A meta-analysis of four baricitinib RCTs in 10,815 hospitalised COVID-19 patients demonstrated a significant reduction in 28-day mortality. A meta-analysis of all JAK/STAT inhibition data from COVID-19 studies is proposed to identify which…
1 sources - 4 claims
A meta-analysis of four baricitinib RCTs in 10,815 hospitalised COVID-19 patients demonstrated a significant reduction in 28-day mortality. A meta-analysis of all JAK/STAT inhibition data from COVID-19 studies is proposed to identify which patient subgroups benefit most. The FDA granted emergency authorisation for baricitinib combined with remdesivir for hospitalised COVID-19 patients requiring respiratory support. Early pandemic data from China and Italy suggested that JAK inhibitors could rapidly resolve symptoms in severe COVID-19.